CraniUS Therapeutics Founder Dr. Chad Gordon Featured on Brain In Progress Podcast
BALTIMORE — CraniUS Therapeutics today announced that Founder and Executive Chairman Dr. Chad Gordon was recently featured on the Brain In Progress podcast, where he discussed the clinical challenges that led to the development of the company’s NeuroPASS™ platform.
In the episode, Dr. Gordon shares the origin of CraniUS and the fundamental problem the company is working to address: the inability to reliably deliver therapies across the blood brain barrier. This limitation continues to restrict treatment options for patients with neurological disease, despite advances in drug development.
The discussion explores how NeuroPASS is being developed as a fully implantable platform designed to enable targeted, programmable delivery of therapeutics directly to the brain, and what it will take to translate this approach into clinical practice.
CraniUS Therapeutics is advancing NeuroPASS toward clinical and regulatory milestones as part of its broader mission to redefine how brain diseases are treated through direct therapeutic access.
The full episode is available across platforms:
Listen here: https://linktr.ee/brain.in.progress
About CraniUS Therapeutics
CraniUS Therapeutics is a neurotechnology company developing a fully implantable platform designed to bypass the blood brain barrier and enable long-term, programmable drug delivery to the brain. The company is headquartered in Baltimore, Maryland and is advancing its NeuroPASS™ platform toward clinical studies.
About CraniUS
CraniUS™ Therapeutics is a neurotechnology company developing the first fully implantable platform to bypass the blood-brain barrier for long-term, programmable drug delivery. Its flagship device, NeuroPASS™, is designed to transform the treatment landscape for debilitating neurological conditions across multiple disease types by leveraging the temporal skull space. CraniUS Therapeutics is headquartered in Baltimore, Maryland, and collaborates globally with industry leading experts in neurosurgery, drug delivery, implant design, device engineering, and manufacturing.
Important Regulatory Notice
NeuroPASS™ is an investigational device and has not been approved or cleared by the U.S. Food and Drug Administration for clinical use. All described uses are under development and subject to regulatory review.
Media Contact:Elizabeth DaleExecutive Advisor, Strategic Partnerships & External Relationsedale@craniusmed.comwww.craniusmed.com
